Drugs / HPV 16 E6 peptides
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01653249 | Aug 2012 → Jul 2015 | human papilloma virus infection | University of Arkansas | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02481414 | Nov 2015 → Sep 2022 | cervical intraepithelial neoplasia | University of Arkansas | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HPV-16 E6 peptides | “HPV 16 E6 peptides combined with Candin®” NCT02481414 ↗ |
| Modality | Vaccine | “a vaccine consisting of four HPV-16 E6 peptides in combination with Candin®” NCT01653249 ↗ |
| Route | Other | “administered intradermally in the extremities” NCT02481414 ↗ |